May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Microparticles for Targeted Drug Delivery to Inflamed Vasculature
Author Affiliations & Notes
  • Z. Zhang
    Potentia Pharmaceuticals Inc., Louisville, Kentucky
  • F. Grossi
    Potentia Pharmaceuticals Inc., Louisville, Kentucky
  • S. Potdar
    Potentia Pharmaceuticals Inc., Louisville, Kentucky
  • M. Singh
    Potentia Pharmaceuticals Inc., Louisville, Kentucky
  • E. Sullivan
    Potentia Pharmaceuticals Inc., Louisville, Kentucky
  • C. Vega
    Potentia Pharmaceuticals Inc., Louisville, Kentucky
  • O. Kachurina
    VasDesign Corporation, Orlando, Florida
  • A. Kachurin
    VasDesign Corporation, Orlando, Florida
  • C. Francois
    Potentia Pharmaceuticals Inc., Louisville, Kentucky
  • P. Olson
    Potentia Pharmaceuticals Inc., Louisville, Kentucky
  • Footnotes
    Commercial Relationships  Z. Zhang, Potentia Pharmaceuticals, E; F. Grossi, Potentia Parmaceuticals Inc, E; S. Potdar, Potentia Pharmaceuticals Inc, E; M. Singh, Potentia Pharmaceuticals Inc, E; E. Sullivan, Potentia Pharmaceuticals Inc, E; C. Vega, Potentia Pharmaceuticals Inc, E; O. Kachurina, VasDesign Corporation, E; A. Kachurin, VasDesign Corporation, E; C. Francois, Potentia Pharmaceuticals Inc, E; P. Olson, Potentia Pharmaceuticals Inc, E.
  • Footnotes
    Support  NIH Grant EY017518
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3190. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Z. Zhang, F. Grossi, S. Potdar, M. Singh, E. Sullivan, C. Vega, O. Kachurina, A. Kachurin, C. Francois, P. Olson; Microparticles for Targeted Drug Delivery to Inflamed Vasculature. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3190. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The purpose of this study was to develop a drug delivery microparticle that could selectively home to activated endothelial cells in vivo.

Methods: : Homing is achieved by surface-decorating the particles with sialyl-Lewis x (sLex), a tetrasaccharide that binds to the selectins present on activated endothelial cells. Poly (lactide-co-glycolide) (PLGA) and poly (ethylene imine) (PEI) were used as the polymer matrix to construct the particles. Coumarin-6-loaded particles were prepared by a modified water/oil/water emulsion technique and characterized for mass and size distribution. In vitro and in vivo inflammation models were used to study the homing of the particles.

Results: : In vitro data indicated that the particles could efficiently encapsulate POT-4, a potent cyclic peptide complement inhibitor, and release it over 60 days in PBS. The sLex conjugated particles preferentially bound to activated endothelial cells over resting cells, and this specific binding was decreased significantly by addition of anti-sLex antibody.

Conclusions: : sLex conjugated microparticles may be used as a drug delivery vehicle homing to the sites of inflammation.

Keywords: inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×